

Special Issue

Modulating Therapeutic Properties of Oral Tissue-Derived Mesenchymal Stem Cells

Message from the Guest Editor

Mesenchymal stem cells have been shown to exhibit significant regenerative potential and have also shown immunomodulatory properties, allowing them to be introduced into a host without eliciting any adverse immune response. Additionally, mesenchymal stem cells have been shown to exhibit tropism toward injured/pathological sites, thus allowing for a targeted therapeutic modality. Oral-tissue-derived mesenchymal stem cells have gained popularity due to their ready availability, especially mesenchymal stem cells derived from the exfoliated human primary tooth and the human permanent tooth extracted for orthodontic purposes. Despite the increasing number of applications of oral-tissue-derived mesenchymal stem cells, their regenerative potential has been shown to exhibit limitations. The present Special Issue will focus on the augmentation of the regenerative potential of oral-tissue-derived mesenchymal stem cells through pre-conditioning with various pharmaceutical agents.

Guest Editor

Dr. Luca Testarelli

Department of Oral and Maxillo-Facial Sciences, Sapienza University of Rome, 00161 Rome, Italy

Deadline for manuscript submissions

closed (30 June 2022)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 4.1
Indexed in PubMed



mdpi.com/si/84050

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 4.1
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.4 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the second half of 2024).